Highlights Mesoblast Limited

Equities

MSB

AU000000MSB8

Delayed Australian S.E. Other stock markets 11:51:10 2024-06-12 pm EDT			5-day change	1st Jan Change
1.098 ^AUD	+2.57%		+7.07%	+254.03%

May. 01	Mesoblast Limited Announces Board and Committee Changes	CI
Apr. 01	ADRs End Higher; Connect Biopharma Climbs 26%	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ADRs End Higher; Connect Biopharma Climbs 26%	Apr. 01	DJ
ADRs End Lower; NuCana Slides 15%	Mar. 28	DJ
Top Premarket Gainers	Mar. 26	MT
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application	Mar. 26	DJ
Mesoblast to Resubmit Application for Potential Pediatric Treatment of Graft Versus Host Disease; Shares Gain Pre-Bell	Mar. 26	MT
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease	Mar. 25	CI
Top Stories at Midday: Bally's Gets Takeover Proposal; Eli Lilly's Eczema Study Results; Reddit's Expected IPO Price Range; FDA Backs Mesoblast Heart Therapy's Approval Pathway	Mar. 11	MT
Mesoblast Secures Backing from US FDA for Potential Fast-Track Approval of Heart Failure Treatment	Mar. 11	MT
Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device	Mar. 10	CI
Mesoblast Narrows H1 FY24 Loss; Shares Down 3%	Feb. 28	MT
Mesoblast Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Mesoblast Says FDA Grants Orphan Drug Designation for Revascor in Children With Congenital Heart Disease	Feb. 15	MT
Mesoblast Secures US FDA Orphan Drug Designation for Cell Therapy; Shares Jump 7%	Feb. 14	MT
Mesoblast Secures Rare Pediatric Disease Designation with US FDA for Cell Therapy Medication; Shares Rally 14%	Jan. 18	MT
Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment	Jan. 18	DJ
United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease	Jan. 18	CI
Rights Issue: 1 new share @ 0.3 AUD for 4 existing shares	Dec. 04	FA
Key Inflation Data, Fed Comments Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Monday	Nov. 27	MT
Mesoblast Files for Orphan Drug, Rare Pediatric Disease Designations for Severe Heart Disease Treatment	Nov. 27	MT
Mesoblast Files Orphan Drug, Pediatric Rare Disease Designation Application to US FDA for Cell Therapy; Shares Rise 3%	Nov. 26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mesoblast Limited

Equities

MSB

AU000000MSB8

Highlights

Filters